In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10797539 | PMC |
| http://dx.doi.org/10.1182/blood.2023021274 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SOHO State of the Art Updates and Next Questions | Diffuse Large B-Cell Lymphoma in Older Adults: A Comprehensive Review.
Clin Lymphoma Myeloma Leuk
November 2024
Memorial Sloan Kettering Cancer Center, New York City, NY. Electronic address:
Article Synopsis
- Older adults with diffuse large B-cell lymphoma (DLBCL) face unique challenges and poorer outcomes, highlighting the need for tailored care strategies.
- Geriatric assessment (GA) tools, like simplified GA (sGA), help categorize patients into fit, unfit, and frail groups to guide treatment decisions, including dose adjustments for chemotherapy.
- New treatment options, including CAR-T cell therapy and bispecific antibodies, are evolving to better serve older adults, particularly those who are unable to tolerate traditional therapies or who experience relapse after initial treatment.
How I Treat Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Blood
October 2024
University of Rochester Medical Center, Rochester, New York, United States.
Article Synopsis
- * New treatment options are emerging; however, determining which are safe and effective for older patients, especially in cases of relapse, remains complicated and requires careful assessments.
- * The article outlines strategies for managing older adults with relapsed DLBCL, including advanced therapies like CAR-T cell therapy and other innovative treatments tailored for this age group.
Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy.
Blood Adv
October 2024
Department of Hematology, Centre Henri Becquerel, Rouen, France.
Tafasitamab plus lenalidomide (TAFA-LEN) treatment relevance pre- or post-anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is debated. We analyzed patients with large B-cell lymphoma in the DESCAR-T registry treated with axi[1]cel or tisa-cel in ≥3rd line and TAFA-LEN before (n = 15, "TL-pre-CAR-T" set) or directly after (n = 52, "TL-post-CAR-T" set) CAR T-cell therapy. We compared TAFA-LEN v.
View Article and Find Full Text PDFBlockade of the CD47/SIRPα checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab.
Haematologica
December 2024
Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen.
Article Synopsis
- Macrophages play a crucial role in the effectiveness of the anti-CD19 antibody tafasitamab, which is used to treat certain types of lymphoma.
- The study focuses on the CD47-SIRPα interaction, which can inhibit the macrophages' ability to effectively eliminate tumor cells, and suggests that blocking CD47 may boost tafasitamab's effectiveness.
- Experimental results showed that combining tafasitamab with an anti-CD47 antibody improved phagocytosis of lymphoma cells and resulted in better outcomes in animal models, indicating potential for clinical application.
Time-dependent cost comparison and health economic impact analysis of second-line interventions for transplant-ineligible patients with relapsed or refractory diffuse large B cell lymphoma.
Eur J Haematol
September 2024
VITIS Healthcare Group, Cologne, Germany.
Objectives: Novel interventions (axicabtagene ciloleucel [axi-cel], lisocabtagene maraleucel [liso-cel], tafasitamab-lenalidomide [Tafa-L], polatuzumab-rituximab-bendamustine [pola-BR]) improve clinical outcomes in second-line (2 L) treatment of transplant-ineligible patients with early relapse or refractory (R/R) diffuse large B cell lymphoma (DLBCL). The costs vary depending on the respective treatment regimen and the treatment duration, difficult comparability in reimbursement decisions. The objective was to analyze the health economic impacts of novel 2 L interventions and conventional immunochemotherapies (bendamustine-rituximab [BR], rituximab-gemcitabine-oxaliplatin [R-GemOx]) from a German healthcare payer's perspective as a function of treatment duration.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!